Merck’s $32 Billion Crisis? 3 Dividend Stocks to Buy & HOLD for the Next Decade!
Did you know a pharmaceutical giant like Merck is poised to lose nearly half its revenue by 2030, yet analysts still recommend it as a top long-term hold? While the artificial intelligence frenzy drives speculative trades, a quiet revolution in dividend investing suggests overlooked opportunities. Merck, despite its Keytruda patent cliff, is aggressively acquiring new treatments like Ohtuvayre and TERN-701, boasting a pipeline promising $70 billion in new annual revenue. Similarly, Verizon Communications offers stability in a mature market, delivering consistent returns even without explosive growth. Discover how these proven businesses can anchor your portfolio for the next decade by embracing quality over fleeting trends. Don't miss out on more insights into resilient investments; be sure to subscribe to our channel!
Tags/Hashtags: #merck #verizon #keytruda #investing #merck #nvidia #intel
Leave a Reply